![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Safety and Tolerability of Elbasvir/Grazoprevir in Patients With Chronic Hepatitis C: An Integrated Analysis of Phase 2-3 Trials
|
|
|
Reported by Jules Levin
AASLD 2015 Nov 13-17 San Francisco
Dusheiko GM1; Manns MP2; Vierling JM3; Reddy KR4; Sulkowski M5; Kwo P6; Lawitz E7; Brown DD8; Klopfer SO8; Robertson M8; Wahl J8; Barr E8; Haber B8; Charles ED8*
1University College London, Institute of Liver and Digestive Health, Royal Free Hospital, London, UK; 2Medical School of Hannover, Hannover, Germany; 3Baylor St. Luke's Medical Center, Houston, TX, USA; 4University of Pennsylvania, Philadelphia, PA, USA; 5Johns Hopkins University School of Medicine, Baltimore, MD, USA; 6Indiana University School of Medicine, Indianapolis, IN, USA; 7The Texas Liver Institute, University of Texas
Health Science Center, San Antonio, TX, USA; 8Merck & Co., Inc., Kenilworth, NJ, USA. *Former employee of Merck & Co., Inc.
![AASLD1.gif](../images/010416/010416-4/AASLD1.gif)
![AASLD2.gif](../images/010416/010416-4/AASLD2.gif)
![AASLD3.gif](../images/010416/010416-4/AASLD3.gif)
![AASLD4.gif](../images/010416/010416-4/AASLD4.gif)
![AASLD5.gif](../images/010416/010416-4/AASLD5.gif)
![AASLD6.gif](../images/010416/010416-4/AASLD6.gif)
![AASLD7.gif](../images/010416/010416-4/AASLD7.gif)
![AASLD8.gif](../images/010416/010416-4/AASLD8.gif)
![AASLD9.gif](../images/010416/010416-4/AASLD9.gif)
![AASLD10.gif](../images/010416/010416-4/AASLD10.gif)
![AASLD11.gif](../images/010416/010416-4/AASLD11.gif)
![AASLD12.gif](../images/010416/010416-4/AASLD12.gif)
![AASLD13.gif](../images/010416/010416-4/AASLD13.gif)
![AASLD14.gif](../images/010416/010416-4/AASLD14.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|